February 2024 Investor Update Presentationhttps://spectraldx.com/wp-content/uploads/2024/02/spectral-medical-investor-Feb2024.pdf From page 17
Upcoming Catalysts
• Achieved Tigris interim 90 patient enrollment - Baxter paid milestone payment #2 (~Feb/24)
• Baxter's 'Vantiv' spin-off...EDT’s distribution agreement to transfer to ‘Vantive’ spin-off
• Tigris last patient enrollment (“LPE”) - 150 patients (~Q4/24)
• Tigris topline results (LPE + 60 days)
• PMX FDA submission (~Q2/25)
• PMX FDA approval / Baxter milestone payment #3 (H2/25)
• Commence PMX commercialization (late 2025/early 2026)